Ceribell, Inc. (CBLL) AI Stock Analysis

• Market Cap: $657.08M
• Dividend Yield: N/A
• Average Volume (3M): 306.88K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.84
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 281
• Sector: Healthcare
• Sector Strength: 59
• Industry: Medical - Devices
• EPS (TTM): -0.36
• Shares Outstanding: 36,143,020
• 10 Day Avg. Volume: 261,402
• 30 Day Avg. Volume: 306,876
• PEG Ratio: 0.00
• Price to Book (P/B): -6.75
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -17.93
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: 2.74
• Enterprise Value/Gross Profit: 8.60
• Enterprise Value/Ebitda: -4.78
• 1Y Price Target: $31.80
• Price Target Upside: 84.13% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 59 Neutral
• Price Target: $18.50 ▲(7.12%Upside)

Ceribell, Inc. receives a moderate score of 59. The company's robust revenue growth and strategic advancements are tempered by significant profitability challenges and cash management issues. Technical indicators favor short-term momentum, but the lack of valuation clarity and increased expenses present risks.

Positive Factors

Expansion Opportunities

Management is confident in the company’s strong underlying fundamentals continuing with further momentum expected from expansion opportunities.

Financial Guidance

The company raised its full-year revenue guidance to a range of $83M to $87M, which implies growth of 27% to 33%.

Revenue Growth

CBLL reported a strong 1Q performance which saw the company deliver total revenue of $20.5M, up 42% from the same period last year.

Negative Factors

Manufacturing Concerns

The company is assessing all potential options for manufacturing relocation, including moving to Mexico or other geographies in Asia.

Stock Price Decline

The stock has fallen 35% largely due to China manufacturing exposure and lock-up expiration.

Tariff Headwinds

Potential headwinds from incremental tariffs are not expected to impact margins until the fourth quarter.

Ceribell, Inc. Business Overview & Revenue Model

Company Description

CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company develops Ceribell System, a novel, point-of-care EEG platform to address the unmet needs of patients in the acute care setting. It also offers EEG disposable headbands; and pocket-sized battery-operated recorders. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, California.

How the Company Makes Money

Ceribell, Inc. generates revenue primarily through the sale of its EEG systems to hospitals and medical institutions. The company's revenue model includes the direct sale of its EEG hardware, as well as recurring revenue from the consumables and accessories required for the operation of these systems. Additionally, Ceribell may offer service contracts and training for healthcare providers to ensure proper usage and maintenance of their equipment. Significant partnerships with hospitals, healthcare systems, and potentially government health bodies could contribute to the company's earnings by facilitating broader adoption of their technology.

Ceribell, Inc. Financial Statement Overview

Summary

Ceribell, Inc. demonstrates strong revenue growth and improved equity, suggesting financial stability. However, negative net profit margins, high operating expenses, and reliance on external financing reveal significant profitability and cash management challenges.

Income Statement

Ceribell, Inc. shows solid revenue growth of 44.7% from 2023 to 2024, highlighting strong demand for their products. However, the company is operating at a loss with a negative net profit margin, and EBIT and EBITDA margins indicate inefficiencies. Gross profit margins are strong at approximately 86.7% for 2024, signifying good production cost management but are overshadowed by the high operating expenses.

Balance Sheet

The company's equity has significantly improved from negative to a strong positive position in 2024, indicating strong financial backing or recent capital infusion. The debt-to-equity ratio is low due to high equity, showcasing low leverage risk. However, the equity ratio is high at 84.8%, reflecting a stable asset base primarily funded by equity.

Cash Flow

Ceribell's free cash flow is negative but has shown improvement from 2023. The high operating cash outflows are concerning, relative to the negative net income, indicating cash management issues. A significant financing cash flow in 2024 suggests reliance on external funding to cover operational deficits.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement		Total Revenue
71.08M	65.44M	45.23M	25.92M
	Gross Profit
62.01M	56.75M	38.16M	21.49M
	EBIT
-45.47M	-39.71M	-30.04M	-36.02M
	EBITDA
-43.74M	-37.71M	-26.51M	-35.06M
	Net Income Common Stockholders
-44.50M	-40.45M	-29.46M	-37.16M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
182.70M	194.37M	34.49M	68.23M
	Total Assets
213.47M	225.41M	58.92M	86.46M
	Total Debt
21.76M	21.96M	14.20M	18.22M
	Net Debt
-131.60M	-172.41M	-20.29M	-50.02M
	Total Liabilities
20.76M	34.25M	171.17M	172.86M
	Stockholders Equity
180.88M	191.16M	-112.25M	-86.40M
Cash Flow		Free Cash Flow
-39.90M	-36.38M	-30.14M	-32.52M
	Operating Cash Flow
-38.18M	-35.04M	-29.16M	-32.00M
	Investing Cash Flow
-30.56M	-1.60M	-1.76M	-1.40M
	Financing Cash Flow
192.68M	196.52M	-2.82M	49.80M

Ceribell, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IRMD	80 Outperform	$757.31M	37.61	23.81%	1.17%	11.04%	9.84%
CBLL	59 Neutral	$657.08M	―	26.25%	―	―	―
AXGN	56 Neutral	$457.26M	―	-7.22%	―	18.81%	67.41%
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
AVNS	52 Neutral	$559.55M	45.80	-36.78%	―	1.34%	-530.36%
BFLY	50 Neutral	$603.39M	―	-29.16%	―	25.77%	49.44%
RXST	44 Neutral	$577.45M	―	-11.98%	―	46.69%	46.68%

Ceribell, Inc. Corporate Events

Ceribell, Inc. Announces Results of Annual Meeting

On June 10, 2025, Ceribell, Inc. held its Annual Meeting of Stockholders, where two key proposals were voted on. The stockholders elected Juliet Tammenoms Bakker and Lucian Iancovici, M.D. as Class I directors to serve until the 2028 meeting, and approved the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (CBLL) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Ceribell, Inc. stock, see the CBLL Stock Forecast page.

Ceribell, Inc. Addresses Impact of New U.S. Tariffs

Ceribell, Inc. has addressed the potential impact of newly announced U.S. tariffs on goods imported from China, which affect the company’s headband product manufactured by Chinese contractors. The company anticipates no significant financial impact from these tariffs until the fourth quarter of 2025 due to existing inventory, but expects an 8 to 10 percentage point reduction in gross margins once current inventory is depleted. The tariffs are not expected to affect the cost of revenue from subscription products.

Ceribell, Inc. Announces Executive Compensation Adjustments

On March 10, 2025, Ceribell, Inc. announced adjustments to the compensation packages of its top executives, effective April 1, 2025. The Board of Directors approved increases in the annual base salaries and target annual incentives for CEO Xingjuan (Jane) Chao, CFO Scott Blumberg, and CTO Raymond Woo, reflecting the company’s commitment to retaining key leadership.